HIPEC and Cytoreductive Surgery for Peritoneal Mesothelioma: Who Qualifies and What to Expect

For most cancers, the lining of the abdomen is not where the conversation starts. For peritoneal mesothelioma, it is the entire conversation. The disease grows on the peritoneum, the thin membrane that wraps the abdominal organs, and it spreads across that surface in sheets and nodules rather than as a focal mass. That biology is what has made cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) the central treatment decision for people who qualify.

This is a guide for patients and families trying to make sense of that decision. It pulls from the largest peer-reviewed series, the PSOGI international consensus, and the National Cancer Institute’s Mesothelioma Treatment PDQ. It does not include law-firm marketing language, and it does not promise outcomes that the published data do not support. The goal is to give readers the same vocabulary and framing that surgical and medical oncology teams use when they evaluate a patient for this operation.

What CRS and HIPEC Are

Cytoreductive surgery is a long, careful operation that aims to remove every visible tumor deposit from the lining of the abdomen and from any abdominal organ surfaces where the disease has settled. Surgeons use a series of techniques known collectively as peritonectomy procedures, stripping involved peritoneum from the diaphragm, pelvis, lateral abdominal walls, and visceral surfaces. Bowel, omentum, spleen, gallbladder, and parts of the diaphragm or other organs are often resected when they carry tumor.

HIPEC, the second half of the procedure, is delivered immediately after the cytoreduction is complete, while the patient is still in the operating room. A heated chemotherapy solution is circulated through the abdominal cavity for a defined period, typically 60 to 90 minutes at temperatures around 42 to 43 degrees Celsius. The PSOGI consensus identifies cisplatin plus doxorubicin as the recommended HIPEC drug regimen for peritoneal mesothelioma, although institutional practice varies. The intent of HIPEC is to bathe any microscopic disease left behind after cytoreduction with chemotherapy at concentrations and temperatures that intravenous administration could not achieve.

The combination is performed in a single anesthetic. From skin incision to final closure, the operation commonly runs eight to twelve hours, sometimes longer.

Why Peritoneal Mesothelioma Is Treated Differently from Pleural

Pleural mesothelioma, the chest-cavity form, has dominated the mesothelioma literature because it is more common and because the major immunotherapy trials, including CheckMate-743, were built around it. Peritoneal mesothelioma is a different disease in clinically meaningful ways.

The peritoneum is a closed surface. Disease that stays confined to that surface, even when extensive, is in principle accessible to the surgeon in a way that diffuse pleural disease often is not. That accessibility is the reason CRS+HIPEC became standard care for peritoneal mesothelioma earlier and more decisively than aggressive surgery did for pleural disease. The National Cancer Institute’s Mesothelioma Treatment PDQ lists cytoreductive surgery with intraperitoneal chemotherapy alongside systemic therapy with pemetrexed and a platinum agent as the standard treatment options for peritoneal mesothelioma.

Peritoneal mesothelioma is also overrepresented among younger patients and patients with germline BAP1 mutations, which both shift the calculus toward an aggressive surgical approach when it is feasible.

Who Qualifies for CRS+HIPEC

Eligibility is not binary. The published consensus and the major institutional series describe a layered evaluation that includes disease extent, histology, performance status, and feasibility of complete cytoreduction.

Disease extent: the Peritoneal Cancer Index

The Peritoneal Cancer Index (PCI), developed by Paul Sugarbaker, scores tumor burden across 13 abdominopelvic regions on a 0 to 39 scale. Each region receives a lesion size score from 0 (no visible tumor) to 3 (tumor greater than 5 cm or confluent), and the regional scores are summed. PCI is usually estimated on imaging and confirmed at diagnostic laparoscopy or at the start of the operation itself. The PSOGI consensus identifies PCI greater than 20 as generally a contraindication to CRS+HIPEC, while individualized decisions are still possible at experienced centers.

Histology

Yan and colleagues identified epithelioid histology as one of three independent prognostic factors in their multi-institutional series. Sarcomatoid and biphasic peritoneal mesothelioma carry a worse prognosis after CRS+HIPEC, and many programs are more cautious about offering the operation to people with a sarcomatoid component.

Performance status and comorbidities

PSOGI consensus aligns CRS+HIPEC with people of good performance status, typically ECOG 0 or 1, and adequate organ function. The operation is long, the perioperative course is taxing, and recovery requires the cardiopulmonary and renal reserve to tolerate substantial fluid shifts and a lengthy ICU stay.

Lymph node status

Yan and colleagues identified lymph node involvement as the third independent adverse prognostic factor. Imaging and intraoperative assessment of regional lymph nodes are part of the workup at high-volume programs.

Feasibility of complete cytoreduction

The Completeness of Cytoreduction (CCR or CC) score grades how much disease remains after the operation: CC-0 means no visible residual disease, CC-1 means residual nodules under 2.5 mm, CC-2 means residual nodules between 2.5 mm and 2.5 cm, and CC-3 means nodules above 2.5 cm or confluent disease. CC-0 and CC-1 are the targets that drive the survival data. Patients whose preoperative imaging suggests that complete cytoreduction is unlikely are often steered toward systemic therapy first, with reassessment afterward.

What the Published Outcomes Show

The largest body of evidence for CRS+HIPEC in peritoneal mesothelioma comes from a 2009 multi-institutional registry analysis published in the Journal of Clinical Oncology by Yan, Deraco, Baratti, and colleagues. The study pooled 405 patients treated between 1980 and 2008 across eight high-volume institutions in Europe, North America, Australia, and Asia.

The headline numbers from that series:

• Median overall survival was 53 months, with a 95% confidence interval of 45 to 64 months
• Survival rates were 86% at 1 year, 62% at 3 years, and 47% at 5 years
• Perioperative mortality was 2%, and Grade III/IV perioperative morbidity was 54%
• Independent prognostic factors on multivariate analysis were epithelioid histology, completeness of cytoreduction, and lymph node status

These numbers are most useful when read in context. They reflect a selected population that high-volume programs judged to be appropriate for the operation. They do not translate directly to outcomes for patients with sarcomatoid disease, very high PCI, or nodal involvement. They also predate the routine use of pemetrexed-based systemic therapy as part of multimodal management, which several centers have since incorporated.

Single-institution series from established CRS+HIPEC programs, including the Washington Cancer Institute series led by Dr. Paul Sugarbaker, have reported broadly comparable outcomes in patients selected for complete cytoreduction. The PSOGI consensus describes survival in the range of 30 to 50 months when CC-0 or CC-1 is achieved, with notably worse outcomes when cytoreduction is incomplete.

The Center Volume Effect

CRS+HIPEC for peritoneal mesothelioma is one of the more technically demanding operations in cancer surgery. Outcomes depend on factors that accumulate with experience: how aggressively a program pursues complete cytoreduction, how it manages multi-visceral resections, how it runs the HIPEC perfusion, and how it handles the perioperative course in the ICU.

Polanco and colleagues at the University of Pittsburgh reported that perioperative mortality in their CRS+HIPEC program decreased significantly as institutional experience grew, falling from 4.1% in their early era to 1.0% in their more recent era. The pattern is consistent across published institutional learning curves. The same operation, performed at different points in a program’s experience, has materially different perioperative risk.

Levine and colleagues at Wake Forest reported their experience with 1,000 consecutive CRS+HIPEC procedures across a range of histologies, including peritoneal mesothelioma. The series is one of the largest single-institution datasets in the field, and it underscores the volume threshold that distinguishes programs with deep peritoneal surface malignancy expertise from programs that perform CRS+HIPEC infrequently.

The practical implication is direct: peritoneal mesothelioma is not a disease for the local hospital that occasionally takes a peritoneal carcinomatosis case. Patients evaluated by their local oncologist as potential CRS+HIPEC candidates should be referred to one of the programs that has a defined peritoneal mesothelioma practice. The MesoWatch directory of mesothelioma cancer centers can help families identify programs by region.

Recovery and Survivorship

The recovery from CRS+HIPEC is on a different scale from a routine abdominal operation. Most published programs describe an ICU stay of three to seven days, a total hospital stay typically in the range of two to three weeks, and a longer convalescence at home before energy and weight stabilize. Nutritional support is often needed during and after the hospitalization, and patients commonly lose meaningful weight in the first month.

Bowel function takes time to return. Multi-visceral resection, prolonged anesthesia, and intraperitoneal chemotherapy together produce a sluggish gut that may require nasogastric drainage for the first several days. Pain control, drain management, and wound care extend the hands-on phase of recovery for two to four weeks after discharge.

Surveillance after CRS+HIPEC is structured around early detection of resectable recurrence. The PSOGI consensus recommends close follow-up with imaging every 3 to 6 months in the first two years, then every 6 months through year 5, then annually. CT of the chest, abdomen, and pelvis is the workhorse modality, supplemented by clinical exam and tumor markers when those were elevated preoperatively. Recurrence does happen, sometimes years out, and a fraction of patients are candidates for repeat CRS+HIPEC at experienced centers.

Quality of life after recovery is, in published series of selected long-term survivors, generally good. Patients return to work, travel, and most prior activities. The trade-off they accepted, a long operation and a hard recovery, is the reason the survival numbers in the registry data look the way they do.

What This Means for Patients and Families

Two practical takeaways come out of the published literature.

First, peritoneal mesothelioma is treated differently from pleural mesothelioma for biological reasons, not historical accident. The peritoneum is accessible to the surgeon in ways the pleural surface is not, and the data supporting CRS+HIPEC in selected patients are stronger and longer-running than the surgical data for pleural mesothelioma. Patients newly diagnosed with peritoneal disease, or families evaluating a treatment recommendation, should make sure that a high-volume CRS+HIPEC program is in the consult sequence, not as an afterthought.

Second, eligibility is specific. PCI, histology, lymph node status, performance status, and feasibility of complete cytoreduction together determine whether the operation is the right next step. A patient who does not qualify today may still qualify after neoadjuvant systemic therapy at a center that has a clear protocol for that pathway. The decision is not binary, and it is rarely made at a single visit.

The same biology that makes peritoneal mesothelioma a hard diagnosis to recognize, given the overlap with stage-4 abdominal symptoms and the late presentation in many cases, is also what creates the surgical opportunity when the disease is caught while it remains confined to the peritoneal surface. The work for the patient and family is to find the program that can give them an honest assessment of where they fall on that spectrum.

For more on the surgeon who developed the operation and the staging tools that define eligibility, see the authority profile of Dr. Paul Sugarbaker on this site.

Frequently Asked Questions